ESTRO 2024 - Abstract Book

S1607

Clinical - Lung

ESTRO 2024

across study arms (logrank p=0.983 and 0.715, respectively). There have been three cases of in-field disease progression, with one in the control arm and two in the dose-painted arm.

Conclusion:

For LA-NSCLC patients receiving definitive chemoradiotherapy, risk-adapted radiotherapy de-escalation may improve patient-reported outcomes and reduce the risk of treatment-related immunosuppression without compromising disease control. Follow-up studies testing this approach are warranted.

Keywords: IMRT, patient-reported outcomes, randomized trial

References:

1. Ettinger, D.S., et al., NCCN Guidelines® Insights: Non – Small Cell Lung Cancer, Version 2.2023: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 2023. 21(4): p. 340-350.

2. Bradley, J.D., et al., Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non – small-cell lung cancer. Journal of Clinical Oncology, 2020. 38(7): p. 706. Kong, F.-M.S., et al., NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid treatment PET-based) chemoradiotherapy for stage III NSCLC — Results and comparison to NRG-RTOG 0617 (non personalized RT dose escalation). 2021, Wolters Kluwer Health. 4. Iyengar, P., et al., Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. JAMA Oncol, 2021. 3.

5. Dess, R.T., et al., Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non – Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017: p. JCO. 2016.71. 6142.

6. Le Pechoux, C., et al., Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. The Lancet Oncology, 2022. 23(1): p. 104-114.

7. Ohri, N., et al., Positron Emission Tomography – Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology* Biology* Physics, 2017.

446

Digital Poster

Role of prophylactic cranial irradiation for patients with limited disease small cell lung cancer